Daily Archives: May 1, 2023
SPATIAL CONCORDANCE OF LEFT AND RIGHT COLON FINDINGS IN PEDIATRIC PATIENTS WITH ULCERATIVE COLITIS AFTER TREAMTENT
Achieving endoscopic remission has become the preferred clinical endpoint in the care of inflammatory bowel disease (IBD) patients. This requires repeat colonoscopy in patients with ulcerative colitis (UC) after initiation of therapy. Recent adult data… Continue reading
DEMOCRATIC DELIBERATION TO ASSESS VETERAN PREFERENCES FOR BIOSIMILAR MEDICATION SWITCHING FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN A RESOURCE CONSCIOUS SETTING
To optimize care while being resource conscious, the Veterans Health Administration (VHA) must develop equitable policies that incorporate Veterans’ values and beliefs. Switching patients with Inflammatory Bowel Disease (IBD) from biologic medications … Continue reading
NON-MEDICAL SWITCHING FROM INFLIXIMAB TO A BIOSIMILAR IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE
Studies in adults with inflammatory bowel disease (IBD) have demonstrated that a one-time switch from the originator to a biosimilar has not resulted in loss of response, increased side effects, or antibody development. Data describing non-medical swit… Continue reading
A NURSE LED INTERVENTION TO IMPROVE ACCESS TO CARE USING A TELEPHONE TRIAGE ALGORITHM
Inflammatory bowel disease is a chronic inflammatory condition for which patients may require care on a more urgent basis. Response times can be delayed when clinics are inundated with calls or when providers are not available for immediate patient car… Continue reading
ERYTHEMA NODOSUM AND PYODERMA GANGRENOSUM IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD), ulcerative colitis (UC), and indeterminate colitis (IC), affects 77/100,000 children in the US. It is estimated that 2-5% of children with UC and 1-10% of children with CD experience a c… Continue reading
WHOLE EXOME SEQUENCING OF A MULTIPLEX CROHN’S DISEASE FAMILY IDENTIFIES RARE ALTERATIONS IN PYGB ANDXRN2 AS POTENTIALLY HIGH IMPACT RISK VARIANTS OF DISEASE
The study of multiplex Crohn’s disease (CD) families has played a critical role in our understanding of the disease, including the identification of the first recognized CD risk variants in NOD2, which remain among the highest impact genetic predisposi… Continue reading
PRO-INFLAMMATORY SIRPα-EXPRESSING MONOCYTES AND MACROPHAGES MEDIATE ANTI-TNF REFRACTORY CROHN’S DISEASE IN CHILDREN
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with detrimental consequences on the pediatric population. Anti-tumor necrosis factor (aTNF) therapies are the only FDA-approved biologics for pediatric CD but one-th… Continue reading
ASSESSMENT OF THE IMMUNE CELL LANDSCAPE IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Disease (IDB) is a chronic and sometimes refractory group of gastrointestinal conditions that can cause enormous medical and socioeconomic burdens. [1] Both, innate and adaptive immune cells play a crucial role in the pathogenesis of… Continue reading
YIELD OF SERIAL TESTING FOR TUBERCULOSIS EXPOSURE IN THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT WITH INFLAMMATORY BOWEL DISEASES (SPARC IBD)
More than 2 million Americans have Inflammatory Bowel Diseases (IBD), including Crohn’s Disease or Ulcerative Colitis. Although tuberculosis is uncommon in the United States, patients with IBD are at an increased risk for active tuberculosis infection … Continue reading
ANALYSIS OF THE GENETIC EXPRESSION OF COLON CANCER GENETIC BIOMARKERS ON INFLAMMATORY BOWEL DISEASE ON BLOOD AND BIOPSY SAMPLES
Inflammatory bowel disease (IBD) is an immune-mediated inflammatory condition of the gastrointestinal tract. Its incidence rose steadily in the last century and the estimated incidence is approximately 2.5 million in Europe and 1.5 million in North Ame… Continue reading